{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:25Z","timestamp":1792839745733,"version":"4.5.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2017,8,26]],"date-time":"2017-08-26T00:00:00Z","timestamp":1503705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,8,26]],"date-time":"2017-08-26T00:00:00Z","timestamp":1503705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct\u2010acting antiviral\u2013based therapies remains unclear. In this multicenter, open\u2010label, phase 2 study, we evaluated the efficacy and safety of a fixed\u2010dose combination of sofosbuvir\u2010velpatasvir (400 mg\/100 mg) plus weight\u2010adjusted ribavirin administered for 24 weeks in patients who did not achieve sustained virologic response after prior treatment with direct\u2010acting antiviral regimens that included the nucleotide analogue nonstructural protein 5B inhibitor sofosbuvir plus the nonstructural protein 5A inhibitor velpatasvir with or without the nonstructural protein 3\/4A protease inhibitor voxilaprevir. The primary efficacy endpoint was the proportion of patients achieving sustained virologic response at 12 weeks after the cessation of treatment. In total, 63 of 69 (91%; 95% confidence interval, 82%\u201097%) patients achieved sustained virologic response at 12 weeks, including 36 of 37 (97%; 95% confidence interval, 86%\u2010100%) patients with hepatitis C virus genotype 1 infection, 13 of 14 (93%; 95% confidence interval, 66%\u2010100%) patients with genotype 2 infection, and 14 of 18 (78%; 95% confidence interval, 52%\u201094%) patients with genotype 3 infection. Most adverse events were of mild or moderate severity. The most frequently reported adverse events were fatigue, nausea, headache, insomnia, and rash. One patient (1%) with genotype 1a infection discontinued all study drugs due to an adverse event (irritability). <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> Retreatment of patients who previously failed direct\u2010acting antiviral\u2013based therapies with sofosbuvir\u2010velpatasvir plus ribavirin for 24 weeks was well tolerated and effective, particularly those with hepatitis C virus genotype 1 or 2 infection. (H<jats:sc>epatology<\/jats:sc> 2017;66:1083\u20101089).<\/jats:p>","DOI":"10.1002\/hep.29256","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T08:59:05Z","timestamp":1494579545000},"page":"1083-1089","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":80,"title":["Sofosbuvir\u2010velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct\u2010acting antiviral regimen"],"prefix":"10.1097","volume":"66","author":[{"given":"Edward J.","family":"Gane","sequence":"first","affiliation":[{"name":"Auckland Clinical Studies,Auckland,New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell L.","family":"Shiffman","sequence":"additional","affiliation":[{"name":"Liver Institute of Virginia,Richmond,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Etzkorn","sequence":"additional","affiliation":[{"name":"Borland Groover Clinic,Jacksonville,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Morelli","sequence":"additional","affiliation":[{"name":"University of Florida,Gainesville,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.M.","family":"Stedman","sequence":"additional","affiliation":[{"name":"Christchurch Hospital and University of Otago,Christchurch,New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell N.","family":"Davis","sequence":"additional","affiliation":[{"name":"South Florida Center of Gastroenterology,Wellington,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Hinestrosa","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center,Orlando,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Dvory\u2010Sobol","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.","family":"Huang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Osinusi","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McNally","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Brainard","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"McHutchison","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Thompson","sequence":"additional","affiliation":[{"name":"St. Vincent's Hospital,Melbourne,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sulkowski","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine,Baltimore,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"GS\u2010US\u2010342\u20101553 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,8,26]]},"reference":[{"key":"hep29256-bib-0001-20250714","first-page":"51","article-title":"Interferon\u2010free combination therapies for the treatment of hepatitis C: current insights","volume":"7","year":"2015","journal-title":"Hepat Med"},{"key":"hep29256-bib-0002-20250714","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1756283X15587481","article-title":"The changing landscape of hepatitis C virus therapy: focus on interferon\u2010free treatment","volume":"8","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"hep29256-bib-0004-20250714","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct\u2010acting antiviral drugs in interferon\u2010free regimens","volume":"151","year":"2016","journal-title":"Gastroenterology"},{"key":"hep29256-bib-0005-20250714","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance\u2010associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","year":"2016","journal-title":"Gastroenterology"},{"key":"hep29256-bib-0007-20250714","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep29256-bib-0008-20250714","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep29256-bib-0009-20250714","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep29256-bib-0010-20250714","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct\u2010acting antiviral therapy for hepatitis C virus infection","volume":"37","year":"2017","journal-title":"Liver Int"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.29256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201710000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T07:00:39Z","timestamp":1752476439000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201710000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,26]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.29256","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,26]]},"assertion":[{"value":"2017-03-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}